

ORTOMA PUBLISHES INFORMATION DOCUMENT REGARDING THE RIGHTS ISSUE

The Board of Directors of Ortoma AB (publ) (“Ortoma” or the “Company”) publishes information document in connection with the rights issue of approximately SEK 52 million, before transaction costs, which was resolved by the Board of Directors on 3 March 2026 and subsequently approved by the extraordinary general meeting held on 24 March 2026 (the “Rights Issue”).

The Information Document

In connection with the Rights Issue, the Company has prepared an information document (the “**Information Document**”) in accordance with Article 1.4 (db) of Regulation (EU) No 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC, as amended (the “**Prospectus Regulation**”). The Information Document has been prepared in accordance with the requirements set out in Annex IX to the Prospectus Regulation.

Ortoma announces today that the Information Document has been registered with the Swedish Financial Supervisory Authority (Finansinspektionen) and is available on the Company’s website, www.ortoma.com

Timetable for the Rights Issue

Trading in subscription rights	31 March – 10 April 2026
Subscription period	31 March – 15 April 2026
Trading in paid subscribed shares (BTA)	31 March – 22 April 2026
Publication of outcome	On or about 17 April 2026
Trading in new shares[1]	28 April 2026

Advisors

DNB Carnegie Investment Bank AB acts as Sole Global Coordinator and Sole Bookrunner in connection with the Rights Issue. NORMA Advokater KB is legal adviser to the Company.

Important information

Publication, release, or distribution of this press release may in certain jurisdictions be subject to legal restrictions and persons in the jurisdictions where the press release has been made public or distributed should be informed of and follow such legal restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer or solicitation to buy or subscribe for any securities in Ortoma AB (publ) in any jurisdiction, either from Ortoma AB (publ) or from anyone else. This press release is not a prospectus according to the definition

in the Prospectus Regulation and has not been approved by any regulatory authority in any jurisdiction. A disclosure document prepared in accordance with Article 1.4 (db) and Annex IX of the Prospectus Regulation regarding the Rights Issue described in this press release has been prepared and published by the Company prior to the commencing of the subscription period.

This press release does not constitute an offer or solicitation to buy or subscribe for securities in the United States. The securities mentioned herein may not be sold in the United States without registration, or without an exemption from registration, under the U.S. Securities Act from 1933 (“**Securities Act**”), and may not be offered or sold within the United States without being registered, covered by an exemption from, or part of a transaction that is not subject to the registration requirements according to the Securities Act. There is no intention to register any securities mentioned herein in the United States or to issue a public offering of such securities in the United States. The information in this press release may not be released, published, copied, reproduced or distributed, directly or indirectly, wholly or in part, in or to United States, Australia, Hongkong, Israel, Canada, Japan, South Africa, New Zealand, Switzerland, Singapore, Russia, Belarus, South Korea or any other jurisdiction where the release, publication or distribution of this information would violate current rules or where such an action is subject to legal restrictions or would require additional registration or other measures beyond those that follow from Swedish law. Actions in contravention of this instruction may constitute a violation of applicable securities legislation.

Please note that an investment in the Company is subject to regulation under the Foreign Direct Investment Act (2023:560), which requires investors, under certain conditions, to notify and obtain approval from the Swedish Inspectorate for Strategic Products. Investors should make their own assessment of whether a notification obligation exists before making any investment decision.

[1] Note that depending on different routines at different banks and custodians the trading may begin before or after this date

For further information, please contact:

Yvonne Mårtensson, Chairman of the Board

Fredrik Strömberg, CEO

E-post: info@ortoma.com

About Us

Ortoma AB develops surgical systems for the planning and positioning of implants in hip, knee and spinal surgery. The purpose of the company's surgical system, Ortoma Treatment Solution™ (OTS) is to enable surgeons to accurately measure and plan 3D surgery for the placement of joint implants, and during surgery, to optimally position the implant in the patient. Ortoma's surgical system is aimed at providing better patient outcomes, fewer complications and less follow-up surgeries – and thus better long-term survival rates for implants. OTS is a system that is easily integrated into the processes and routines currently used in surgery, thereby increasing efficiency. Globally, more than 7.5 million orthopedic procedures are performed each year where OTS could be used in hip, knee and spinal surgery. Ortoma's B shares are listed on Nasdaq First North Growth Market Stockholm. Redeye Nordic Growth AB is Certified Adviser for Ortoma. For more information see: www.ortoma.com

Attachments

[Ortoma publishes information document regarding the rights issue](#)